
About
MindWalk is an antibody discovery company serving pharma, biotech, and academic partners. It provides end-to-end discovery, development, optimization, and protein production services for therapeutic, diagnostic, and research biologics from sites in the USA, Canada, and Belgium.
Services
Antibody discovery, development, and optimization
End-to-end antibody discovery from target analysis through optimized lead selection using wet-lab workflows and AI-enabled analysis.
Therapeutic antibody discovery
Function-first discovery and development of therapeutic antibodies selected for function, not just binding.
Anti-drug and anti-idiotype antibody discovery
Discovery of anti-drug and anti-idiotypic antibodies with reproducible data packages and validated assays.
Diagnostic antibody discovery
Discovery of diagnostic antibodies designed for high affinity, sensitivity, specificity, reproducibility, and scalable performance.
Research antibody discovery
Discovery of antibodies for research and analytical applications, including custom solutions for challenging targets.
Protein engineering, expression, and production
Design, expression, and production of recombinant proteins and antibody formats, from sequence to purified protein.
LensAI analysis
AI analysis for epitope mapping, paratyping, developability, immunogenicity, and candidate evaluation.
MindWalk Collaborative
Events, webisodes, and collaborative forums for biologics R&D.
11 more services
- Antibody discovery programs
- B cell Select® discovery
- B cell Llama™ VHH discovery
- Hybridoma discovery
- Yeast display discovery
- Therapeutic antibodies
- Anti-drug & anti-idiotype antibodies
- Diagnostic antibodies
- Protein engineering & production
- ReefIQ™
- LensAI™
- Turnaround
- 3 weeks to 12 weeks
Capabilities
- Assays and studies
- Antibodies
- Hybridoma
- Immunogenicity
- Bispecifics
- Epitope mapping
- Paratyping
11 more
- Developability assessment
- Immunogenicity screening
- Candidate evaluation
- Binding affinity optimization
- Target specificity assessment
- Selectivity assessment
- Western blot
- IHC
- Flow cytometry
- Developability
- Anti-drug-antibody risk prediction
- Scale and capacity
- 100 µg–1 mg
- 10–50 mg
- Gram-scale production
- Over 20 publicly disclosed client antibodies have entered the clinic
- Ten in the clinic today
- Four first in class
- 3,000 times
- Therapeutic areas
- Oncology
- Infectious disease
- Neurodegeneration
- Metabolic disease
- Rare disease
- Inflammation
- Drug discovery
Instruments and platforms
- X-ray crystallography
Modalities and species
- Modalities
- Antibody
- Bispecific
- Peptide
- Recombinant protein
- Vaccine
- Species and models
- Rabbit
- Chicken
- Camelid
- Mouse
- HEK293
- CHO
- E. coli
- Camelid immune repertoire
Industries served
- Biotech
- Pharma
- Academic research
- Biologics
- Drug discovery
- Diagnostics
Company
- Type
- CRDMO
- Founded
- 2019
- Quality
- >98% discovery success rate (B cell Select® discovery success rate) · 100% success rate (anti-idiotypic antibody discovery to date) · #1 antibody discovery and development co (Roots Analysis (2022)) · LensAI won the 2024 InterSystems Impact (outperforming more than 1,000 global biotherapeutic research projects) · Patented HYFT® technology (EP3881326)
Locations
- Office
- 823 Congress Ave Suite 300 Austin, TX 78701, USA
- Sites
- Austin, USA · Fargo, USA · Diepenbeek, Belgium
- Serves
- USA, Canada, Europe, global
Contacts
- Phone
- +1 (800) 620-4187
Public records
- Wikidata
- Q30282844 source